There are currently 13 active clinical trials seeking participants for Celiac Disease research studies. The states with the highest number of trials for Celiac Disease participants are California, Florida, Texas and Massachusetts.
Tissue Destruction and Healing in Celiac Disease
NCT05680012
Recruiting
The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particular, this study will examine the interactions between biological factors such as, intestinal epithelial cells, microbiota, immune system, genetics, and gluten and their effect on celiac disease clinical symptoms, and severity of tissue destruction and its ability to heal in individuals with celiac disease. Information collected in the study will help researchers to generate bett... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/10/2025
Locations: California Institute of Technology, Pasadena, California +2 locations
Conditions: Celiac Disease
Register for Updates
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
NCT06557772
Recruiting
This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE). The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/25/2024
Locations: Ventura County Gastroenterology Medical Group- Site Number : 8400010, Camarillo, California +64 locations
Conditions: Coeliac Disease, Celiac Disease
Register for Updates
Urine Metabolites in the Diagnosis of Disease
NCT06710067
Recruiting
The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases. This research study intends to enroll participants across a range of demographics and GI disease states including colorectal cancer, small intestinal bacterial overgrowth (SIBO), Crohn\'s disease, and Celiac disease, collect urine samples and clinical data, and use artificial intelligence and machine learning t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Unio Health Partners (Gastroenterology), Encinitas, California +3 locations
Conditions: Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Crohn Disease, Celiac Disease
Register for Updates
VTP-1000 in Adults With Celiac Disease
NCT06310291
Recruiting
GLU001 is a first-in-human clinical trial to assess the safety and tolerability of VTP-1000 for adults with celiac disease. This trial will assess VTP-1000 at various dose levels compared to placebo in a single ascending dose (SAD) and multiple ascending dose (MAD) format. Participants will be followed for a short period of time to assess the impact of VTP-1000 on their immune system (Adverse events, reactions in the blood, and physical exam differences). Participants enrolled in the MAD portion... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/09/2024
Locations: Parexel EPCU LA, Los Angeles, California +3 locations
Conditions: Celiac Disease
Register for Updates
Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission
NCT05636293
Recruiting
Subjects include: aged 18 to 75 years, inclusive, have biopsy-confirmed disease that is clinically inactive as determined by negative celiac disease (CeD) serology and histology (determined via endoscopy at time of screening), have followed a gluten-free diet (GFD) for ≥6 months as reported by the subject, and be human leukocyte antigen (HLA)-DQ2.5 and/or HLA-DQ8 positive. Study involves the following randomized intervention; 10g gluten + 200mg of Ritlecitinib or placebo
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/19/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Celiac Disease
Register for Updates
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study
NCT02061306
Recruiting
Celiac disease (CD) is a complex disease caused by eating gluten, a protein contained in wheat, rye, and barley. It is well known that many factors contribute to the development of CD, including the genes that you have and the foods that you eat. In the CDGEMM study, we will consider as many of these factors as possible and study how they each contribute to disease development. If the investigators find that any one factor, or combination of factors, increases the risk of developing CD, we will... Read More
Gender:
ALL
Ages:
6 months and below
Trial Updated:
11/19/2024
Locations: Massachusetts General Hospital for Children, Boston, Massachusetts +1 locations
Conditions: Celiac Disease
Register for Updates
Gluten Technology and Education for Celiac Health
NCT06059716
Recruiting
The investigators propose to plan for a multi-center randomized controlled trial (M-RCT) to test the effectiveness of novel gluten detection technologies as an adjunct to telemedicine to manage celiac disease in newly diagnosed adults. If successful, the proposed intervention will improve mucosal recovery, promote a shift in current practice of celiac disease management toward long-term monitoring, and represent a significant step toward reducing the severe physical and psychological consequence... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/09/2024
Locations: University of Chicago Medical Center, Chicago, Illinois +3 locations
Conditions: Celiac Disease
Register for Updates
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients with Autoimmune Disease
NCT06587828
Recruiting
The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation. These tissues contain both cytotoxic and helper T cells that are driving their disease, and these T cells are being guided by TCRs that recognize tissue-specific targets. By collecting tissue when a patient has active inflammation, it is possible to determine which T cells are activated and undergoing clonal e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2024
Locations: Arizona Arthritis & Rheumatology, PLLC, Phoenix, Arizona +21 locations
Conditions: Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (nr-axSpA), Crohn's Disease, Birdshot Chorioretinitis
Register for Updates
Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet
NCT04530123
Recruiting
The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease (CeD) on a gluten-free diet (GFD). Participants will receive TAK-101 and/or placebo through the vein on Day 1 and Day 8. All participants will receive active treatment at Week 24.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/03/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +88 locations
Conditions: Celiac Disease
Register for Updates
Immune Responses to Gluten
NCT05209568
Recruiting
This is a study of immune responses after eating gluten powder in people with celiac disease and healthy controls.
Gender:
All
Ages:
Between 2 years and 101 years
Trial Updated:
06/03/2024
Locations: Children's Hospital Colorado, Aurora, Colorado +1 locations
Conditions: Celiac Disease, Malabsorption Syndromes, Digestive System Disease, Intestinal Disease, Gastrointestinal Diseases, Gluten Sensitivity, Celiac Disease in Children
Register for Updates
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
NCT05635266
Recruiting
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/03/2024
Locations: Sanguine Biosciences, Waltham, Massachusetts
Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Register for Updates
General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
NCT04477928
Recruiting
In partnership with Helmsley Charitable Trust, the Sanford PLEDGE Study is a large-scale, observational, feasibility study of general population screening for T1D and celiac autoantibodies. Screening is incorporated into routine health care visits within an integrated health system.
Gender:
All
Ages:
Between 0 minutes and 17 years
Trial Updated:
04/19/2024
Locations: Sanford Bemidji Region Clinics, Bemidji, Minnesota +3 locations
Conditions: Type 1 Diabetes, Celiac Disease
Register for Updates